<?xml version="1.0" encoding="UTF-8"?>
<p>Analysis of pharmacological databases allows quickly selection of “candidates,” already having assessments of their biosafety and stability, but it is unlikely that a “breakthrough” drug will be obtained at the exit. However, these approaches buy time to treat people while longer studies are still pending.</p>
